Welcome to our dedicated page for Jin Medical SEC filings (Ticker: ZJYL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Jin Medical International Ltd. filings document foreign private issuer reports furnished on Form 6-K, including Nasdaq minimum bid price compliance, shareholder meeting materials, press releases and manufacturing facility updates. The filings identify Jin Medical as a Cayman Islands exempted company with operations centered on rehabilitation medical equipment and wheelchair-related products in China.
Recent regulatory disclosures cover the company’s completed 1-for-20 share consolidation, the reclassification of its ordinary shares into Class A and Class B ordinary shares, and related amendments to its authorized share capital. The record also includes extraordinary general meeting notices, proxy materials, incorporation-by-reference language for an F-3 registration statement, and updates on the Chuzhou facility and Class I Medical Device production license.
Jin Medical International Ltd. reported insider information for director Xue Ning through an initial beneficial ownership statement. The report identifies Ning as a director of Jin Medical but does not list any non-derivative or derivative equity holdings or any insider transactions in the company’s securities as of this filing.
Jin Medical International Ltd. reported that independent director Dr. Jiayuan (James) Tong resigned from the board on July 9, 2026, effective immediately, and stepped down from all committee roles. The company stated that his resignation was not due to any disagreement over operations, policies, or practices.
On July 13, 2026, the board appointed Ning Xue as an independent director, effective July 14, 2026, to fill the vacancy. He becomes chairperson of the Nominating and Corporate Governance Committee and a member of the Audit and Compensation Committees. The board determined he meets Nasdaq and SEC audit committee independence requirements.
Under an Independent Director Agreement, Mr. Xue will serve an initial term from July 14, 2026 to March 27, 2027 and receive US$14,082 in compensation, payable quarterly, plus expense reimbursement. An Indemnification Agreement provides him protection against certain liabilities related to his board service. This governance update is incorporated by reference into the company’s Form F-3 registration statement.
Jin Medical International is amending a prior report mainly to update proxy materials and meeting logistics for July 20, 2026, when Class A holders, Class B holders and all shareholders will vote on major governance and transaction changes.
Key proposals include increasing Class B voting rights from thirty to eight hundred votes per share while Class A stays at one vote, a share capital increase from 45,000,000 to 15,000,000,000 authorized Class A shares, and adopting a new memorandum and articles to reflect these changes. Shareholders will also vote on a related-party repurchase of 3,769,057 Class A shares from Jolly Harmony at a 90‑day VWAP, cancelling them, and issuing 3,769,057 Class B shares to Jolly Harmony at the same VWAP.
Another centerpiece is acquiring contractual control of Beijing Tongsheng Technology via a VIE structure, paying an aggregate US$105,329,974 in the form of 64,186,456 Class A shares at US$1.641 each, plus an expected 6,418,646 Class A shares to Goldeenridge Ventures as advisory compensation. If all steps close, the Seller group would hold about 81.84% of outstanding ordinary shares but only around 1.65% of voting power, while Jolly Harmony would own about 6.08% of shares yet control roughly 98.11% of voting power.
JIN MEDICAL INTERNATIONAL LTD. has agreed to acquire contractual control of Beijing Tongsheng Technology via a variable interest entity (VIE) structure for US$105,329,974, to be paid in 64,186,456 new Class A Ordinary Shares at US$1.641 per share, subject to shareholder and regulatory approvals.
The company also plans to issue an additional 6,418,646 Class A shares to Goldeenridge Ventures Ltd. for advisory services, greatly expanding its equity base. An extraordinary meeting will vote on increasing authorized Class A shares to 15,000,000,000, raising Class B voting rights from 30 to 800 votes per share, and a related-party swap where 3,769,057 Class A shares held by Jolly Harmony are repurchased and replaced with the same number of super‑voting Class B shares, concentrating voting power while leaving economic rights unchanged.
Jin Medical International Ltd. changed its independent auditor, dismissing Audit Alliance LLP effective June 2, 2026, following board approval. Audit Alliance had audited the company for the years ended September 30, 2024 and 2025 and issued no adverse opinions, disclaimers, or qualifications.
The company reports there were no disagreements with Audit Alliance on accounting principles, financial disclosure, or audit scope, and no reportable events under Item 304(a)(1)(v)(A)-(D) of Regulation S‑K. On June 2, 2026, Jin Medical engaged Enrome LLP as its new independent registered public accounting firm for the fiscal year ending September 30, 2026.
The company also notes it had not consulted Enrome LLP on accounting matters or audit opinions during the past two fiscal years before this engagement. This report is incorporated by reference into Jin Medical’s existing Form F-3 registration statement.
Jin Medical International Ltd. director Franklin Oliver St Clair Jr filed an initial Form 3, which is a statement of beneficial ownership for insiders. This filing establishes his status as a director and provides a baseline ownership record, and it reports no transactions or trades in the company’s securities.
Jin Medical International Ltd. director TONG JAMES JIAYUAN has filed an initial Form 3, which identifies him as a director of the company. The filing data provided shows no reported share holdings or transactions, with all buy, sell, and exercise share counts listed as zero.
Jin Medical International Ltd. director Guo Yanru has filed an initial Form 3 as a reporting person for the company’s shares. The filing shows no reported share transactions, no derivative transactions, and no holding entries in this excerpt, effectively establishing a baseline for future insider ownership reports.
Jin Medical International Ltd. director and Chief Executive Officer Wang Erqi reported his beneficial ownership of the company’s ordinary shares. He beneficially owns 4,306,307 Class A Ordinary Shares through Jolly Harmony Enterprises Limited and Er Pu International Limited, and 1,000,000 Class B Ordinary Shares through Jolly Harmony Enterprises Limited, reflecting substantial indirect ownership and control over these holdings.
Jin Medical International Ltd. submitted an initial insider ownership report for Wang Ziqiang. The filing identifies him as both a director and the company’s Chief Financial Officer. The Form 3 does not report any insider share purchases, sales, or other transactions.